Two Sigma Advisers
APYX icon

Two Sigma Advisers’s Apyx Medical APYX Stock Holding History

Two Sigma Advisers’s Portfolio APYX Stock Details APYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-14,300
Closed -$198K – 2612
2021
Q3 		$198K Buy
14,300
+800
+6% +$8.41K ﹤0.01% 2251
2021
Q2 		$139K Buy
+13,500
New +$134K ﹤0.01% 2316

Other funds holding APYX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACM
Archon Capital Management Seattle, Washington $246M AUM 130.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
HKAM
Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $214M AUM 47.29% 1-Year Est. Return

Two Sigma Advisers's APYX Position: Q4 2021 in Review

Two Sigma Advisers sold out of Apyx Medical (APYX) in Q4 2021, closing a stake of 14,300 shares — an estimated $198K sold.

Two Sigma Advisers first reported a position in APYX in Q2 2021 and held it in 2 quarters. The position peaked at $198K in Q3 2021. 75 funds tracked by Wall St. Rank hold APYX as of Q4 2021.

  • Two Sigma Advisers reported no remaining Apyx Medical position as of Q4 2021 after selling out during the quarter.
  • Two Sigma Advisers sold 14,300 Apyx Medical shares in Q4 2021, an estimated $198K.
  • Two Sigma Advisers first reported a position in Apyx Medical in Q2 2021 and held it in 2 quarters.
  • Two Sigma Advisers's Apyx Medical position peaked at $198K in Q3 2021.
  • 75 funds tracked by Wall St. Rank held Apyx Medical as of Q4 2021.

Based on Two Sigma Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.